Fei Xu
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Fei Xu has a total of 62 co-authors. Here are the top co-authors by number of shared publications:
- Anita S. Bowman
Department of Pathology and Laboratory Medicine, Memorial Sloan Kettering Cancer Center, New York, New York
11 shared publications - Alvaro Quintanal-Villalonga
Memorial Sloan Kettering Cancer Center
10 shared publications - Andre L. Moreira
Department of Pathology, NYU Grossman School of Medicine, NYU Langone Health, New York, NY
10 shared publications - Anne Marie Noronha
Marie-Josée and Henry R. Kravis Center for Molecular Oncology, Memorial Sloan Kettering Cancer Center, New York, New York
10 shared publications - Benjamin Herzberg
Division of Hematology and Oncology, Columbia University Irving Medical Center , New York, NY 10032
10 shared publications - Chad Vanderbilt
Department of Pathology and Laboratory Medicine, Memorial Sloan Kettering Cancer Center, New York, USA
10 shared publications
Latest Publications
- 13 June 2025
- Published by Oxford University Press (OUP) in JNCI: Journal of the National Cancer Institute
- Vol. 117 (9) , 1848-1857
Clinical utility and tissue concordance of circulating tumor DNA in pancreatic ductal adenocarcinoma
Background: The utility of circulating tumor DNA (ctDNA) in addressing challenges of molecular tissue profiling and complementing next-generation sequencing is undefined in pancreas ductal adenocarcinoma. The objective of this study was to assess ctDNA detection rates by stage, disease burden, and metastasis patterns; compare overall survival between ctDNA-positive and ctDNA-negative patients cases; and determine concordance between ctDNA and matched-tissue biopsies. Methods: Patients with pancreas ductal adenocarcinoma who had undergone Next Generation Sequencing by the MSK-ACCESS (Memorial Sloan Kettering – Analysis of Circulating cfDNA to Evaluate Somatic Status) ctDNA assay between 2019 and 2022 were included. Clinical and survival data were abstracted from a prospectively maintained clinical database. Results: A total of 414 patients with pancreas ductal adenocarcinoma: 28% stage I-II, 21% stage III, 51% stage IV. ctDNA detection was highest among patients with advanced disease: 75% stage IV, 38% stage III, 34% stage I-II disease. For stage IV, ctDNA was more frequently detected in patients with at least 2 organs involved vs with less than 2 organs involved (76% vs 38%, P = .025). Higher rates of ctDNA detection were observed in patients with liver metastases vs without (82% vs 52%, P < .001). In the untreated stage IV cohort (n = 120), median overall survival was 10 months for those with detectable ctDNA (95% CI = 6.9 to 14 months) vs 19 months (95% CI = 13 months to not reached) for those with undetectable ctDNA (P = .1). Concordance between ctDNA and matched tissue next-generation sequencing was lower in untreated stage I-III disease, but high for untreated stage IV pancreas ductal adenocarcinoma, including a critical success index of 93.1% of KRAS variants. Conclusion: ctDNA is a promising tool in the detection of somatic variants in pancreas ductal adenocarcinoma. Concordance between ctDNA and tissue is high for patients with untreated metastatic disease, notably for detection of KRAS variants.
- 13 June 2025
- Published by Oxford University Press (OUP) in JNCI: Journal of the National Cancer Institute
- Vol. 117 (9) , 1848-1857
Clinical utility and tissue concordance of circulating tumor DNA in pancreatic ductal adenocarcinoma
Background: The utility of circulating tumor DNA (ctDNA) in addressing challenges of molecular tissue profiling and complementing next-generation sequencing is undefined in pancreas ductal adenocarcinoma. The objective of this study was to assess ctDNA detection rates by stage, disease burden, and metastasis patterns; compare overall survival between ctDNA-positive and ctDNA-negative patients cases; and determine concordance between ctDNA and matched-tissue biopsies. Methods: Patients with pancreas ductal adenocarcinoma who had undergone Next Generation Sequencing by the MSK-ACCESS (Memorial Sloan Kettering – Analysis of Circulating cfDNA to Evaluate Somatic Status) ctDNA assay between 2019 and 2022 were included. Clinical and survival data were abstracted from a prospectively maintained clinical database. Results: A total of 414 patients with pancreas ductal adenocarcinoma: 28% stage I-II, 21% stage III, 51% stage IV. ctDNA detection was highest among patients with advanced disease: 75% stage IV, 38% stage III, 34% stage I-II disease. For stage IV, ctDNA was more frequently detected in patients with at least 2 organs involved vs with less than 2 organs involved (76% vs 38%, P = .025). Higher rates of ctDNA detection were observed in patients with liver metastases vs without (82% vs 52%, P < .001). In the untreated stage IV cohort (n = 120), median overall survival was 10 months for those with detectable ctDNA (95% CI = 6.9 to 14 months) vs 19 months (95% CI = 13 months to not reached) for those with undetectable ctDNA (P = .1). Concordance between ctDNA and matched tissue next-generation sequencing was lower in untreated stage I-III disease, but high for untreated stage IV pancreas ductal adenocarcinoma, including a critical success index of 93.1% of KRAS variants. Conclusion: ctDNA is a promising tool in the detection of somatic variants in pancreas ductal adenocarcinoma. Concordance between ctDNA and tissue is high for patients with untreated metastatic disease, notably for detection of KRAS variants.
- Open Access
- 13 January 2025
- Published by American Association for Cancer Research (AACR)
Figure 1 from Chromothripsis-Mediated Small Cell Lung Carcinoma
Cohort selection and clinicopathologic characteristics. A, Schematic diagram of RB1 and TP53 inactivation (outer doughnut) and smoking status (inner doughnut) in a cohort of 600 consecutive SCLC that underwent tNGS by MSK-IMPACT. RB1 and TP53 status was determined based on integrated genomic and IHC data (see “Results”). B, Tabular and (C) pictorial summary of pathologic sample characteristics and sequencing assays performed for 20 patients with aSCLC. See “Methods” for histopathologic criteria. Ki67 not available. D, Summary of metastatic site distribution based on radiologic–pathologic findings (full data in Supplementary Table S2). E–G, Compilation of radiologic and pathologic findings for three representative patients. E, (A01): 19-year-old patient with brain metastasis showing classic undifferentiated morphology of SCLC: small, crowded/molding cells, numerous mitotic figures (>50/2 mm2), apoptotic bodies, and Ki67 of 90%, whereas thoracic sample shows well-differentiated, nested morphology of a carcinoid tumor lacking mitotic figures or apoptotic bodies, and exhibiting Ki67 of 5%–20%. F, Case A08 and (G) case A09 illustrate classic SCLC morphology in primary lung tumor samples, featuring Ki67 rate of 80% and 90%, respectively. n indicates areas of extensive necrosis–a hallmark feature of SCLC. For extended pathologic illustrations, see Supplementary Figs. S1–S4. Scale bars are 100 μm for Ki67 and 50 μm for H&E except for top in F which is 1 mm. H, Comparison of age, Ki67 proliferation index, and smoking pack-years in aSCLC vs. other SCLC (n = 224 for age and Ki67; n = 200 for pack-year smoking). For patients with multiple samples, Ki67 represents the maximal (max) hot-spot rate among all evaluated samples. H&E, hematoxylin and eosin; FNA, fine needle aspiration; Core bx, core biopsy; py, pack-years; tNGS, targeted next-generation sequencing. (C, D created in part with BioRender.com.)
- 13 January 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure 1 from Chromothripsis-Mediated Small Cell Lung Carcinoma
Cohort selection and clinicopathologic characteristics. A, Schematic diagram of RB1 and TP53 inactivation (outer doughnut) and smoking status (inner doughnut) in a cohort of 600 consecutive SCLC that underwent tNGS by MSK-IMPACT. RB1 and TP53 status was determined based on integrated genomic and IHC data (see “Results”). B, Tabular and (C) pictorial summary of pathologic sample characteristics and sequencing assays performed for 20 patients with aSCLC. See “Methods” for histopathologic criteria. Ki67 not available. D, Summary of metastatic site distribution based on radiologic–pathologic findings (full data in Supplementary Table S2). E–G, Compilation of radiologic and pathologic findings for three representative patients. E, (A01): 19-year-old patient with brain metastasis showing classic undifferentiated morphology of SCLC: small, crowded/molding cells, numerous mitotic figures (>50/2 mm2), apoptotic bodies, and Ki67 of 90%, whereas thoracic sample shows well-differentiated, nested morphology of a carcinoid tumor lacking mitotic figures or apoptotic bodies, and exhibiting Ki67 of 5%–20%. F, Case A08 and (G) case A09 illustrate classic SCLC morphology in primary lung tumor samples, featuring Ki67 rate of 80% and 90%, respectively. n indicates areas of extensive necrosis–a hallmark feature of SCLC. For extended pathologic illustrations, see Supplementary Figs. S1–S4. Scale bars are 100 μm for Ki67 and 50 μm for H&E except for top in F which is 1 mm. H, Comparison of age, Ki67 proliferation index, and smoking pack-years in aSCLC vs. other SCLC (n = 224 for age and Ki67; n = 200 for pack-year smoking). For patients with multiple samples, Ki67 represents the maximal (max) hot-spot rate among all evaluated samples. H&E, hematoxylin and eosin; FNA, fine needle aspiration; Core bx, core biopsy; py, pack-years; tNGS, targeted next-generation sequencing. (C, D created in part with BioRender.com.)
- Open Access
- 13 January 2025
- Published by American Association for Cancer Research (AACR)
Figure 5 from Chromothripsis-Mediated Small Cell Lung Carcinoma
Multisample analysis from all temporally or spatially distinct samples obtained for each patient. A, Conservation of chromothripsis and corresponding amplifications across all samples with available data from individual patients. ^ indicates lower purity samples compared with the other sample from same patient (Supplementary Table S5); CN values in such samples may be falsely low. * indicates chromothripsis detected by WGS only, but not detected by tNGS. N/A, not available: sample without NGS or IHC. Sample numbering is chronologic (Supplementary Table S3). B, Multisample analysis showing RB1 and TP53 genomic alterations and expression of pRb, p53, and p16 by IHC, illustrating a subset of patients with acquired or subclonal RB1 alterations/loss (details in Supplementary Table S1) and a subset with unusual patterns of p16 expression (see “Results”). C, Illustration of a case with acquired RB1 mutations and loss of expression in metastatic samples. pRb-positive cells admixed with negative tumor cells in panels on the right are benign lymphocytes and stromal cells, serving as internal controls. Scale bars are 100 μm, except for the left bottom, which is 1 mm. D, RNA-seq for CDKN2A, encoding p16. Arrows indicate cases with chromothripsis of chromosome 12 and ecDNA amplification of CDK4. TPM, transcripts per million. (C, created in part with BioRender.com.)
- 13 January 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure 5 from Chromothripsis-Mediated Small Cell Lung Carcinoma
Multisample analysis from all temporally or spatially distinct samples obtained for each patient. A, Conservation of chromothripsis and corresponding amplifications across all samples with available data from individual patients. ^ indicates lower purity samples compared with the other sample from same patient (Supplementary Table S5); CN values in such samples may be falsely low. * indicates chromothripsis detected by WGS only, but not detected by tNGS. N/A, not available: sample without NGS or IHC. Sample numbering is chronologic (Supplementary Table S3). B, Multisample analysis showing RB1 and TP53 genomic alterations and expression of pRb, p53, and p16 by IHC, illustrating a subset of patients with acquired or subclonal RB1 alterations/loss (details in Supplementary Table S1) and a subset with unusual patterns of p16 expression (see “Results”). C, Illustration of a case with acquired RB1 mutations and loss of expression in metastatic samples. pRb-positive cells admixed with negative tumor cells in panels on the right are benign lymphocytes and stromal cells, serving as internal controls. Scale bars are 100 μm, except for the left bottom, which is 1 mm. D, RNA-seq for CDKN2A, encoding p16. Arrows indicate cases with chromothripsis of chromosome 12 and ecDNA amplification of CDK4. TPM, transcripts per million. (C, created in part with BioRender.com.)
- Open Access
- 13 January 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figures S1-S13 from Chromothripsis-Mediated Small Cell Lung Carcinoma
Supplementary Figure S1. Detailed morphologic and immunohistochemical findings: Case A01. Supplementary Figure S2. Detailed morphologic and immunohistochemical findings: Case A08. Supplementary Figure S3. Detailed morphologic and immunohistochemical findings: Case A17. Supplementary Figure S4. Detailed morphologic and immunohistochemical findings: Case A20. Supplementary Figure S5. Mutational signatures in atypical SCLC (aSCLC), never-smoker SCLC with RB1–/TP53– (nsSCLC) and smoking-associated SCLC (sSCLC) analyzed by MSK-IMPACT. Supplementary Figure S6. Circos plots showing structural variants and copy number alterations across the genome from all cases with WGS. Supplementary Figure S7. Chromothripsis assessment by targeted NGS (MSK-IMPACT) versus WGS. Supplementary Figure S8. RNAseq for non-recurrently amplified (KRAS, ERBB3, KDM5A) or deleted (TGFBR2, ARID1A) genes on chromothriptic chromosomes and TERT. Supplementary Figure S9. Comparison of chromothripsis characteristics in aSCLC vs other major lung cancer types. Supplementary Figure S10. Chromothripsis architecture in all cases profiled by whole-genome sequencing. Supplementary Figure S11. Chromothripsis in multi-sample analysis and genomic alterations in samples with histotype heterogeneity. Supplementary Figure S12. Cell cycle and p53 pathway deregulation in aSCLC. Supplementary Figure S13. Expression of potential therapeutic markers in aSCLC.
- 13 January 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figures S1-S13 from Chromothripsis-Mediated Small Cell Lung Carcinoma
Supplementary Figure S1. Detailed morphologic and immunohistochemical findings: Case A01. Supplementary Figure S2. Detailed morphologic and immunohistochemical findings: Case A08. Supplementary Figure S3. Detailed morphologic and immunohistochemical findings: Case A17. Supplementary Figure S4. Detailed morphologic and immunohistochemical findings: Case A20. Supplementary Figure S5. Mutational signatures in atypical SCLC (aSCLC), never-smoker SCLC with RB1–/TP53– (nsSCLC) and smoking-associated SCLC (sSCLC) analyzed by MSK-IMPACT. Supplementary Figure S6. Circos plots showing structural variants and copy number alterations across the genome from all cases with WGS. Supplementary Figure S7. Chromothripsis assessment by targeted NGS (MSK-IMPACT) versus WGS. Supplementary Figure S8. RNAseq for non-recurrently amplified (KRAS, ERBB3, KDM5A) or deleted (TGFBR2, ARID1A) genes on chromothriptic chromosomes and TERT. Supplementary Figure S9. Comparison of chromothripsis characteristics in aSCLC vs other major lung cancer types. Supplementary Figure S10. Chromothripsis architecture in all cases profiled by whole-genome sequencing. Supplementary Figure S11. Chromothripsis in multi-sample analysis and genomic alterations in samples with histotype heterogeneity. Supplementary Figure S12. Cell cycle and p53 pathway deregulation in aSCLC. Supplementary Figure S13. Expression of potential therapeutic markers in aSCLC.
- Open Access
- 13 January 2025
- Published by American Association for Cancer Research (AACR)
Figure 7 from Chromothripsis-Mediated Small Cell Lung Carcinoma
Outcome and treatment responses. A, Kaplan–Meier analysis of the disease-specific overall survival assessed from the time of diagnosis. B, Pie chart summarizing radiologic treatment response to platinum-based chemotherapy received in any line of therapy. C, Swimmer plot summarizing treatment modalities used and time-on-treatment, with time of pathologic samples collected and analysis performed indicated. CR, complete response; PD, progressive disease; PR, partial response; SD, stable disease.
- 13 January 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure 7 from Chromothripsis-Mediated Small Cell Lung Carcinoma
Outcome and treatment responses. A, Kaplan–Meier analysis of the disease-specific overall survival assessed from the time of diagnosis. B, Pie chart summarizing radiologic treatment response to platinum-based chemotherapy received in any line of therapy. C, Swimmer plot summarizing treatment modalities used and time-on-treatment, with time of pathologic samples collected and analysis performed indicated. CR, complete response; PD, progressive disease; PR, partial response; SD, stable disease.
- Open Access
- 13 January 2025
- Published by American Association for Cancer Research (AACR)
Figure 2 from Chromothripsis-Mediated Small Cell Lung Carcinoma
Mutation and CNA landscape of aSCLC. A, Mutations and CNAs in aSCLC in comparison to the control groups of sSCLC (n = 206) and pulmonary carcinoids (n = 157) analyzed by MSK-IMPACT. OncoPrint summarizing assays performed and overall genomic features: MSI vs. MSS, TMB, and genomic signature (full signature analysis shown in Supplementary Fig. S5). Case A09 lacked a matched normal DNA sample and was therefore excluded from TMB, MSI, and signature analysis. Displayed genomic alterations include selected recurrently altered genes (see Supplementary Tables S5 and S6 for a full list of detected alterations). For patients with multiple samples, the index sample is displayed (see “Methods”). *, P < 0.05; **, P < 0.01; ***, P < 0.001; ****, P < 0.0001. B, Expression of recurrently amplified genes by IHC in two representative cases (scale bars, 100 μm) and (C) by RNA-seq in cases with available data. Arrows in C indicate cases harboring corresponding amplifications. TPM, transcripts per million; MMR, mismatch repair; N/A, not available; MSS, microsatellite stable.
- 13 January 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure 2 from Chromothripsis-Mediated Small Cell Lung Carcinoma
Mutation and CNA landscape of aSCLC. A, Mutations and CNAs in aSCLC in comparison to the control groups of sSCLC (n = 206) and pulmonary carcinoids (n = 157) analyzed by MSK-IMPACT. OncoPrint summarizing assays performed and overall genomic features: MSI vs. MSS, TMB, and genomic signature (full signature analysis shown in Supplementary Fig. S5). Case A09 lacked a matched normal DNA sample and was therefore excluded from TMB, MSI, and signature analysis. Displayed genomic alterations include selected recurrently altered genes (see Supplementary Tables S5 and S6 for a full list of detected alterations). For patients with multiple samples, the index sample is displayed (see “Methods”). *, P < 0.05; **, P < 0.01; ***, P < 0.001; ****, P < 0.0001. B, Expression of recurrently amplified genes by IHC in two representative cases (scale bars, 100 μm) and (C) by RNA-seq in cases with available data. Arrows in C indicate cases harboring corresponding amplifications. TPM, transcripts per million; MMR, mismatch repair; N/A, not available; MSS, microsatellite stable.
- Open Access
- 13 January 2025
- Published by American Association for Cancer Research (AACR)
Figure 3 from Chromothripsis-Mediated Small Cell Lung Carcinoma
Chromothripsis and corresponding cancer gene amplifications and losses. A, Representative Circos plots of SVs and CNAs across the genome by WGS. Outer band shows an ideogram of chromosome positions and cytogenetic bands. Second band depicts total CN, and third band shows minor allele CN. The inner circle depicts SVs as arcs connecting the two relevant genomic points as identified by three algorithms (see “Methods”). CNAs in key cancer genes in the regions of chromothripsis (red, amplifications; blue, deletions) are displayed. Circos plots for all cases are shown in Supplementary Fig. S6. B, CN log ratio plots from the FACETS algorithm displaying the distinctive oscillating CN states on chromosomes with chromothripsis. CN segments are shown in red. Focal segments (<2 MB in size) are shown as enlarged points for visual purposes. Selected amplifications are indicated (yellow). C, Summary of chromosomal location of chromothriptic events in cases analyzed by WGS and tNGS. Also shown are selected amplifications and losses in oncogenes and tumor suppressors, respectively, localized to the chromothriptic chromosomes. Full list is provided in Supplementary Table S7. D, Schematic summary for the rate of major genomic mechanisms detected in the set analyzed by WGS (n = 11) and in the full cohort (n = 20). In the lower diagram, major chromosomes involved by chromothripsis are indicated in the inner doughnut, and corresponding recurrent gene amplifications are indicated in the outer doughnut. E, Total number of SVs identified in samples analyzed by WGS. Variants are color-coded by type. F, Number of fusions predicted in samples with available RNA-seq. G, Diagram illustrating putative enhancer hijacking in case A17 with chromothripsis on chromosome 2 resulting in translocation between SH3RF3 on chromosome 2 and upstream regulatory region of CCND1 on chromosome 11. Epigenetic landscape surrounding the breakpoint was extrapolated from data from multiple tissue types (Epilogos search tool). ChrT, chromothripsis.
- 13 January 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure 3 from Chromothripsis-Mediated Small Cell Lung Carcinoma
Chromothripsis and corresponding cancer gene amplifications and losses. A, Representative Circos plots of SVs and CNAs across the genome by WGS. Outer band shows an ideogram of chromosome positions and cytogenetic bands. Second band depicts total CN, and third band shows minor allele CN. The inner circle depicts SVs as arcs connecting the two relevant genomic points as identified by three algorithms (see “Methods”). CNAs in key cancer genes in the regions of chromothripsis (red, amplifications; blue, deletions) are displayed. Circos plots for all cases are shown in Supplementary Fig. S6. B, CN log ratio plots from the FACETS algorithm displaying the distinctive oscillating CN states on chromosomes with chromothripsis. CN segments are shown in red. Focal segments (<2 MB in size) are shown as enlarged points for visual purposes. Selected amplifications are indicated (yellow). C, Summary of chromosomal location of chromothriptic events in cases analyzed by WGS and tNGS. Also shown are selected amplifications and losses in oncogenes and tumor suppressors, respectively, localized to the chromothriptic chromosomes. Full list is provided in Supplementary Table S7. D, Schematic summary for the rate of major genomic mechanisms detected in the set analyzed by WGS (n = 11) and in the full cohort (n = 20). In the lower diagram, major chromosomes involved by chromothripsis are indicated in the inner doughnut, and corresponding recurrent gene amplifications are indicated in the outer doughnut. E, Total number of SVs identified in samples analyzed by WGS. Variants are color-coded by type. F, Number of fusions predicted in samples with available RNA-seq. G, Diagram illustrating putative enhancer hijacking in case A17 with chromothripsis on chromosome 2 resulting in translocation between SH3RF3 on chromosome 2 and upstream regulatory region of CCND1 on chromosome 11. Epigenetic landscape surrounding the breakpoint was extrapolated from data from multiple tissue types (Epilogos search tool). ChrT, chromothripsis.
- Open Access
- 13 January 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Tables S1-S13 from Chromothripsis-Mediated Small Cell Lung Carcinoma
Supplementary Table S1. Integrated genomic and immunohistochemical results for TP53 and RB1 in aSCLC Supplementary Table S2. Demographic, clinicopathologic and immunohistochemical characteristics: Per patient data Supplementary Table S3. Samples and studies performed: Per sample data Supplementary Table S4. Clinicopathologic comparison aSCLC vs other SCLC Supplementary Table S5. MSK-IMPACT metrics and full results for all samples Supplementary Table S6. Full list of SNV by MSK-IMPACT in aSCLC Supplementary Table S7. Full list of CNA by MSK-IMPACT in aSCLC Supplementary Table S8. RB1 and TP53 non-coding variant annotation by WGS Supplementary Table S9. Full list of SV by WGS in aSCLC Supplementary Table S10. Full list of fusions by RNAseq in aSCLC Supplementary Table S11. Timing of amplifications by WGS: mutTimerR Supplementary Table S12. Immunohistochemical antibodies, protocols and scoring criteria Supplementary Table S13. List of covered genes by targeted NGS (MSK-IMPACT assay): somatic and germline.
- 13 January 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Tables S1-S13 from Chromothripsis-Mediated Small Cell Lung Carcinoma
Supplementary Table S1. Integrated genomic and immunohistochemical results for TP53 and RB1 in aSCLC Supplementary Table S2. Demographic, clinicopathologic and immunohistochemical characteristics: Per patient data Supplementary Table S3. Samples and studies performed: Per sample data Supplementary Table S4. Clinicopathologic comparison aSCLC vs other SCLC Supplementary Table S5. MSK-IMPACT metrics and full results for all samples Supplementary Table S6. Full list of SNV by MSK-IMPACT in aSCLC Supplementary Table S7. Full list of CNA by MSK-IMPACT in aSCLC Supplementary Table S8. RB1 and TP53 non-coding variant annotation by WGS Supplementary Table S9. Full list of SV by WGS in aSCLC Supplementary Table S10. Full list of fusions by RNAseq in aSCLC Supplementary Table S11. Timing of amplifications by WGS: mutTimerR Supplementary Table S12. Immunohistochemical antibodies, protocols and scoring criteria Supplementary Table S13. List of covered genes by targeted NGS (MSK-IMPACT assay): somatic and germline.
- Open Access
- 13 January 2025
- Published by American Association for Cancer Research (AACR)
Figure 4 from Chromothripsis-Mediated Small Cell Lung Carcinoma
Chromosomal architecture of chromothripsis and amplifications. A, Integrated SV and CNA analysis in two representative cases confirming the hallmark features of chromothripsis and suggesting formation of ecDNA and micronucleation as a mechanism of gene amplification and chromothripsis (see “Results”). Allele-specific CN for each genomic segment is shown on the left y-axis. Genomic segments in which the CN is greater than 5 times of chromosomal baseline are indicated as orange shades to highlight the most significant amplification events. Vertical lines and arcs indicate genomic breakpoints and connections of SVs, of which the number of supporting read fragments is shown on the right y-axis. Colors of the SVs are based on the orientation of paired reads. All cases are shown in Supplementary Fig. S10. B, Conceptual diagram explaining the mechanism of chromothripsis and oncogene amplification in aSCLC. C, FISH analysis of case A07 with 3-color probes: MDM2 (red), CDK4 (green), and CCND2 (orange), revealing ecDNA location of amplified genes (so-called “double-minutes”). Sample is of a metaphase spread from a patient-derived xenograft (see “Methods”). D, Summary of FISH results for all tested samples.
- 13 January 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure 4 from Chromothripsis-Mediated Small Cell Lung Carcinoma
Chromosomal architecture of chromothripsis and amplifications. A, Integrated SV and CNA analysis in two representative cases confirming the hallmark features of chromothripsis and suggesting formation of ecDNA and micronucleation as a mechanism of gene amplification and chromothripsis (see “Results”). Allele-specific CN for each genomic segment is shown on the left y-axis. Genomic segments in which the CN is greater than 5 times of chromosomal baseline are indicated as orange shades to highlight the most significant amplification events. Vertical lines and arcs indicate genomic breakpoints and connections of SVs, of which the number of supporting read fragments is shown on the right y-axis. Colors of the SVs are based on the orientation of paired reads. All cases are shown in Supplementary Fig. S10. B, Conceptual diagram explaining the mechanism of chromothripsis and oncogene amplification in aSCLC. C, FISH analysis of case A07 with 3-color probes: MDM2 (red), CDK4 (green), and CCND2 (orange), revealing ecDNA location of amplified genes (so-called “double-minutes”). Sample is of a metaphase spread from a patient-derived xenograft (see “Methods”). D, Summary of FISH results for all tested samples.
- Open Access
- 13 January 2025
- Published by American Association for Cancer Research (AACR)
Figure 6 from Chromothripsis-Mediated Small Cell Lung Carcinoma
Comparison of aSCLC vs. RB1−/TP53− nsSCLC: the dual model of SCLC pathogenesis in never-smokers. A, Lines of evidence for a histogenetic relationship between aSCLC and carcinoids or their progenitors, including histologic evidence of carcinoid histotype in at least one sample (see also Figs. 1C and 5A), expression of a lung carcinoid–specific gene OTP by IHC, or the presence of genomic alteration characteristic of carcinoids. Bottom, expression of OTP by RNA-seq and IHC. N/A, OTP IHC not available. Scale bar in OTP image: 100 μm. B, Lines of evidence for a histogenetic relationship of nsSCLC with NSCLC. C, Distribution of APOBEC mutational signature in aSCLC, nsSCLC, and sSCLC. See also Supplementary Fig. S5 and “Methods” for details. D, Expression of transcriptional subtype markers and (E) YAP1 by IHC. A, ASCL1-dominant; N, NEUROD1-dominant; P, POU2F3; TN, triple-negative. Subtype marker data were available for 15 aSCLC, 13 nsSCLC, and 142 sSCLC. F, Conceptual diagram depicting dual pathogenetic pathways underlying nsSCLC , highlighting carcinoid–SCLC pathway associated with chromothripsis vs. NSCLC–SCLC pathway associated with EGFR mutations and APOBEC signature. TSG, tumor suppressor genes. (F, created in part with BioRender.com.)
- 13 January 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure 6 from Chromothripsis-Mediated Small Cell Lung Carcinoma
Comparison of aSCLC vs. RB1−/TP53− nsSCLC: the dual model of SCLC pathogenesis in never-smokers. A, Lines of evidence for a histogenetic relationship between aSCLC and carcinoids or their progenitors, including histologic evidence of carcinoid histotype in at least one sample (see also Figs. 1C and 5A), expression of a lung carcinoid–specific gene OTP by IHC, or the presence of genomic alteration characteristic of carcinoids. Bottom, expression of OTP by RNA-seq and IHC. N/A, OTP IHC not available. Scale bar in OTP image: 100 μm. B, Lines of evidence for a histogenetic relationship of nsSCLC with NSCLC. C, Distribution of APOBEC mutational signature in aSCLC, nsSCLC, and sSCLC. See also Supplementary Fig. S5 and “Methods” for details. D, Expression of transcriptional subtype markers and (E) YAP1 by IHC. A, ASCL1-dominant; N, NEUROD1-dominant; P, POU2F3; TN, triple-negative. Subtype marker data were available for 15 aSCLC, 13 nsSCLC, and 142 sSCLC. F, Conceptual diagram depicting dual pathogenetic pathways underlying nsSCLC , highlighting carcinoid–SCLC pathway associated with chromothripsis vs. NSCLC–SCLC pathway associated with EGFR mutations and APOBEC signature. TSG, tumor suppressor genes. (F, created in part with BioRender.com.)